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Abstract
For the evaluation of carcinogenicity bioassays a new trend test is proposed
which is based on a maximum of arithmetic, ordinal, and logarithmic re-
gression scores as well as the Williams-type contrasts for either crude pro-
portions or more appropriate poly3-estimates for the tumor-by-time rela-
tionships. This test provides an almost appropriate power for most shapes of
dose-response relationships (including for possible downturn effect at high(er)
dose(s)), common signs of significance (p-value, confidence limits) and the in-
formation on the probable shape. Related software is easily available within
the CRAN-packages tukeytrend, MCPAN, multcomp
1 Introduction
Aim of a long-term carcinogenicity bioassay is the evaluation of the tumori-
genic effect of a compound when it is administered to rodents for most of
their life span [11, 18]. Tumor-site specific incidences ndeveloping a tumor/nat risk
are of primary interest. This means the evaluation of a 2-by-k contingency
table for the randomized design including a negative control group and com-
monly three dose groups (per species and sex) [p0, p1, p2, ..., pk].
Because longer living animals may develop tumors more likely than those
dying earlier, this evaluation of crude tumor proportions could be distorted.
Instead, their mortality-adjusted analysis is recommended [15]. Historically,
the joint testing of age-adjusted tumor lethality for fatal tumors and age-
adjusted tumor prevalence for incidental tumors is performed [20]. This
requires strictly the availability of valid cause-of-death information for each
individual tumor in each individual animal. An alternative without cause-
of-death information is the poly-k adjustment [7] where the number at risk
is a certain function of animal-specific survival times within each dose group.
According to several guidelines [9], [2] this is the primary principle to iden-
tify a dose-dependent increasing trend commonly by the Cochran–Armitage
test and its poly-3 modifications [15]. However, this trend test has a power
problem (i.e. an unnecessary high false negative rate) for selected non-linear
shapes, particularly plateau-like shapes. Already the title of the original
pioneering paper [6]. stated correctly A test for linear linear trends.... Near-
to-linear shapes occur, but real data show a much broader variety of shapes,
e.g. in a rat lifetime bioassay on romosozumab [10] selected tumor incidences
are:
Table 1: 2-by-k contingency tables for rat bioassay on romosozumab
Males Females
Dose in mg/kg/wk 0 3 10 50 0 3 10 50
animals exam. 60 60 60 54 60 60 60 60
Adrenal cortical adenoma 0 2 6 2 6 3 1 7
Benign pheochromocytome in adrenals 4 3 6 3 2 8 2 0
Renal lipoma in kidneys 0 0 0 1 1 0 0 3
C-cell adenoma in thyroid gland 8 10 4 6 5 11 8 8
Iselt cell adenoma in pancreas 1 1 3 4 0 0 3 3
Islet cell carcinoma in pancreas 0 0 3 2 1 0 1 0
Kerartoacanthoma in skin 2 1 7 0 0 1 0 1
In these data really near-to-linear shapes, such as 0, 1, 2, 3 tumor counts
do not occur. I.e. a trend test in toxicology should be sensitive not only
against near-to-linear shapes. Precisely for this reason an isotonic contrast
test [19], multiple contrast tests [5] a Williams-type contrast test [14], a
sequential version of CA-test [5] were recommended as power-robust alter-
native. Not only the power argument is relevant. Whereas a contrast test
considers dose as a qualitative factor, the CA-test (and other regression-type
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tests) as a quantitative covariate. Sometimes, the consideration of control,
low, medium, high dose is appropriate, sometimes the administered dose lev-
els 0, 3, 10, 50 mg/kg/wk. We will show both. And not only a certain sign of
significance: p-value, or confidence limit for the appropriate chosen effect size,
will be provided, but also the probable shape of the dose-response. There-
fore, the Tukey-Williams trend test is proposed here where dose is jointly
considered quantitatively and qualitatively.
For a mortality-adjusted analysis, the poly-3 modification should be avail-
able. Although p-values are recently widespread used, we should carefully
consider the effect size, e.g. risk difference between two groups or odds ra-
tio on the slope of a regression model. Furthermore, body or organ weight
differences may influence the tumor incidences. Therefore, a related adjust-
ment using the analysis of covariance should be available. A further special
issue are downturn effects at high(er) dose(s) possibly caused by overdosing
or limited bioavailability of the higher doses. To limit the false negative deci-
sion rate either pairwise comparisons against control or downturn-protected
trend tests are highly recommended.
2 A Tukey-Williams trend test
Trend tests can be formulated for dose as either a qualitative factor or as
a quantitative covariate. For the former a multiple contrast test can be
used, for the latter the Armitage trend test of linear regression. Because a
comparison against control is of interest, the Williams test [25] is preferable
as a special multiple contrast test. Because not only a linear regression is
interested, the Tukey trend test [24] is used instead of the CA-trend test.
Both tests represent a maximum test Tmax = max(T1, T2, ..., Tξ), whereby
the tests Ti represent studentized contrasts at the first, but at the second 3
regression tests for linear, ordinal and logarithmic dose scores. The global
Tmax test, considering both multiple contrasts and 3 regression models, is
jointly k-variate normal-distributed. However, the common correlation ma-
trix is hard to calculate. The multiple marginal models approach (mmm)
[21] provides the joint distribution of parameter estimates without assuming
a certain multivariate distribution for the data. The variance-covariance ma-
trix of parameter estimates is obtained using derivatives of the log likelihood
function, i.e. without the explicit formulation of the correlation matrix in
linear, generalized linear and generalized linear mixed effects models.
Because both a multiple contrast test and a regression test belong to the class
of linear models, a specific maximum test for both the Williams contrasts and
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the Tukey regression models can be formulated TmaxTukey-Williams accordingly. It
seems somewhat strange to answer one question about a trend alternative
with (3 + k) individual tests. But first of all many possible forms of dose-
response shapes are recognized with corresponding power: from linear to
plateau. Secondly, the test is not too conservative due to the high corre-
lation between these models. Thirdly, the methodological break between
quantitative and qualitative dose models can be overcome. Fourth, adjusted
p-values and (compatible) simultaneous confidence intervals are available for
this Union-Intersection-Test for individual inferences. This joint test princi-
ple is easily available in the CRAN package tukeytrend [12]. The validity
for the classes of lm, glm, glmm models allows very wide specifications, e.g.
for adjusting covariates (like body weight in bioassays) or different effect
sizes, like odds ratio and hazard ratio. On the other hand, this asymptotic
procedure has coverage problems with small ni.
2.1 A Tukey-Williams trend test for crude proportions
The Tukey-Williams trend test for proportions base on a the estimates of
glm-model. The canonical link is the logit function with the odds ratio as
effect size. Both standard Williams and Tukey test use the risk difference as
effect size, which can be achieved by the identity link in the glm-model alter-
natively (under some data conditions). These asymptotic approaches reveal
problems to keep the nominal coverage probability for small sample sizes, and
the common used-NTP-design with ni = 50, 50, 50, 50 is already small under
this perspective. Furthermore, ratio as effect size for multiple contrasts is
rather unstable when considering p0 = 0 which is a relevant data outcome
in long-term carcinogenicity bioassays. Both phenomena can be mitigated
to some extend by the Add-2 data transformation [4], simply adding one
pseudo count to both tumor and no-tumor category in each group. Yes, for
both p-value and confidence limit estimation a bias is introduced hereby, but
the stabilizing effect of this rather simple modification is amazing [23].
The realization of this new trend test by means of the CRAN package
tukeytrend is quite simple, as demonstrated by the following example. The
2-by-k-table data for incidence of squamous cell papilloma in male B6C3F1
mice administered 0, 0.0875, 0.175, 0.35, or 0.70 mM acrylamide [8] are:
1 2 3 4 5
Dose 0 0.0875 0.175 0.35 0.70
No. papilloma 0 2 2 6 6
No. animals at risk 46 45 46 47 44
The simple R-code consists in the glm object for Add2-approximated
4
proportions, the function tukeytrendfit for Tukey and Williams test (the
option ctype stands for contrast type) and the function ghlt (generalized lin-
ear hypothesis tests) from the package multcomp with the multiple marginal
model approach (functions mmm, mlf):
library(tukeytrend)
library(multcomp)
swaOR <-glm(cbind(events+1,(n-events)+1)~dose, data=squam, family= binomial(link="logit"))
tuOR <- tukeytrendfit(swaOR, dose="dose",
scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
summary(glht(model=tuOR$mmm, linfct=tuOR$mlf, alternative="greater"))
The adjusted p-values for the 7 models are shown in Table 2, whereas
a regression model with ordinal dose scores 0,1,2,3,4 reveals the smallest p-
value. The contribution of the Williams contrasts is weak, not surprising for
an alternative pattern of 0, ζ/3, ζ/3, ζ, ζ
Model Test Test stats p-value
Covariate arithmetic 2.42 0.0168
ordinal 2.53 0.0126
logarithmic 2.53 0.0127
Factor C: 0- 0.70 1.96 0.0508
C: 0-(0.35+0.70)/2 1.92 0.0545
C:0- (0.175+0.35+0.70)/3 1.59 0.1050
C: 0- (0.0875+0.175+0.35+0.70)/4 1.44 0.1378
Table 2: Adjusted p-values
Two further side notes: i) when p0 = 0 and ni are small, the Add1
adjustment can be recommended to yield appropriate pseudo-score intervals
[22], ii) the choice of the effect size should be clear a priori, depending on the
randomization, the design and the experimental goal. If this is not the case,
this maximum test principle of highly correlated tests can be used to select
one out of the three effect sizes: difference of proportion, risk ratio or odds
ratio that is most in line with the alternative [16].
2.2 A Tukey-Williams trend test considering multiple
tumors jointly
The Tmax principle allows the consideration of any correlated tests, not only
for between-dose inference, but for multiple correlated endpoints as well.
Although multiple binary endpoints, such as multiple tumor site proportions
are not too high correlated, are related multivariate TmaxTukey-Williams can be
formulated using the multiple marginal models approach (mmm).
As an example for multiple tumors data from the NTP bioassay on
methyleugenol (No. TR491) in female mice with tumors from 89 tumor
sites were selected [3]. The dataset contains the tumor counts together with
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the dose group (0, 37, 75, and 150 mg/kg) and the time of death [1]. For
demonstration purposes, six liver tumor sites were selected (abbreviated with
t24: hepatoblastoma, t25: multiple hepatoblastoma, t27: multiple hepatocel-
lular adenoma, t28: hepatocellular carcinoma, t29: multiple hepatocellular
carcinoma, t30: hepatocholangiocarcinoma
Figure 1: Mosaicplot multiple tumor incidence
Based on the six glm- and tukeyfit objects (tuxx) as in the above univari-
ate case, the joint test is simply realized by the function combtt:
tt5 <- combtt(tu24i, tu25i, tu27i, tu28i, tu29i)
summary(asglht(tt5, alternative="greater"))
The multiplicity-adjusted p-values reveal no trend in either model or tu-
mor site. If the analysis were only performed for the most significant tumor
site and its best model alone, a strongly significant trend would emerge (last
line of the table). This shows the extreme conservatism of multiple binary
data in this approach. Therefore such a test should be used with care and
not in routine.
2.3 A Tukey-Williams test for poly-k estimates
The poly-k test represents a simple mortality-adjusted analysis where the
cause-of-death information is not needed [7]. This adjustment performed well
under several real data conditions and is robust to different tumor lethality
patterns [17]. It accounts the dose-specific mortality by individual weights
wij = (tij/tmax)
k reflecting individual mortality pattern (tij is time of death
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Tumor site Model Test Test stats p-value
t24 Covariate arithmetic 2.91 0.2888
ordinal 3.15 0.2683
logarithmic 3.15 0.2679
Factor C: 0- 150 2.58 0.3213
C: 0-(75+150)/2 2.58 0.3216
C: 0-(37+75+150)/3 2.35 0.3484
tu25 Covariate arithemic 2.05 0.3926
ordinal 1.82 0.4316
logarithmic 1.82 0.4326
Factor C: 0- 150 1.52 0.4955
C: 0-(75+150)/2 0.72 0.7633
C: 0-(37+75+150)/3 0.49 0.8641
tu27 Covariate arithmetic 3.62 0.2350
ordinal 4.44 0.1934
logarithmic 4.42 0.1950
Factor C: 0- 150 4.60 0.1878
C: 0-(75+150)/2 5.09 0.1696
C: 0-(37+75+150)/3 5.38 0.1608
tu28 Covariate arithmetic 0.30 0.9416
ordinal 0.80 0.7318
logarithmic 0.80 0.7299
Factor C: 0- 150 0.52 0.8520
C: 0-(75+150)/2 1.43 0.5189
C: 0-(37+75+150)/3 1.43 0.5194
tu29 Covariate arithmetic 6.41 0.1358
ordinal 6.79 0.1280
logarithmic 6.79 0.1288
Factor C: 0- 150 1 4.84 0.1780
C: 0-(75+150)/2 4.47 0.1935
C: 0-(37+75+150)/3 4.22 0.2041
tu29 alone Covariate logarithmic 6.79 < 0.0001
Table 3: Adjusted p-values
of animal j in dose i). The tuning parameter k is data-dependent and in a
recent NTP report they used in parallel k = 3 and k = 6. The weights result
in adjusted sample sizes n∗i =
∑ni
j=1wij to be used instead of the randomized
number of animals ni. Therefore adjusted proportions p∗i = yi/n∗i are used
instead of the crude tumor proportions pi = yi/ni. As an example the NTP
study on the carcinogenic potential of methyleugenol for the incidence of skin
fibromas is used [3]. By means of the CRAN package MCPAN the wij, n∗i , p∗i
can be easily estimated The R code is for differences of proportions as effect
size:
fitpoly3 <- glm(tumour ~ dose, data=me,
family=binomial(link="identity"), weight=weightpoly3)
library(tukeytrend)
ttpoly3 <- tukeytrendfit(fitpoly3, dose="dose",
scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
glht(model=ttpoly3$mmm, linfct=ttpoly3$mlf, alternative="greater")
Notice, the mmm approach allows easily a maximum test over many
correlated tests, not only over covariate and factor, over dose scores and
contrasts, but also over several tuning parameter k. In the last line of the
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Table 4: Crude and Poly-3-adjusted tumor rates in the skin fibroma example
dose 0 mg/kg 37 mg/kg 75 mg/kg 150 mg/kg
Crude Rate 1/50 9/50 8/50 5/50
Crude Percent 2.0% 18.0% 16.0% 10.0%
Poly-3 adjusted Rate yi/n∗i 1/41.4 9/40.3 8/38.7 5/32.7
Poly-3 adjusted Percent p∗i 2.4% 22.3% 20.7% 15.3%
Poly-k Model Comparisons Test stats p-value
3 Covariate arithmetic 1.77 0.082
ordinal 2.50 0.015
logarithmic 2.48 0.017
Factor C: 0-150 1.91 0.062
C: 0-(75+150)/2 3.03 0.0032
C: 0-(37+75+150)/3 3.83 0.0002
6 Factor C: 0-(37+75+150)/3 3.97 0.00013
Table 5: Poly-k trend test
table, the minimal p-value of such a 12-variate test is given, i.e. k = 6 and
the plateau alternative are the most likely. Using this example the robustness
of the TmaxTukey-Williams against downturn effects at high doses is good to see.
3 Biological gradient as key criterion
That the presence of a significant dose-response dependency is used as a cen-
tral criterion in the sense of Hill (biological gradient) in the evaluation of
multiple glyphosate assays [13] should be supported. But how was this actu-
ally implemented? Above, the analysis of a global pooled table (Table 20f)
was discussed as inappropriate. The analysis of individual studies remains,
here as an example Study 7 in Tab. 11 was selected. The separate evaluation
of prematurely and terminally died animals is hardly comprehensible from a
statistical point of view, but shows clearly different mortality patterns. This
would have indicated a poly-k trend test, which unfortunately is not feasi-
ble due to missing single values. For hepatocellular adenoma in males the
conclusion [13] was ’While not statistically significant using the Fishers exact
test, the difference was statistically significant for total male rats using the
Peto test for trend. However, there was no evidence of pre-neoplastic foci,
no evidence of progression to adenocarcinomas, and no dose-response.’ The
2-by 4 table is (corrected for ni ≤ 52):
The TmaxTukey-Williams provides a p-value of parithmetic = 0.024 (one-sided ad-
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1 2 3 4
Dose 0 121 361 1214
No. hepatocellular adenoma 0 2 0 6
No. animals at risk 52 52 52 52
Table 6: 2-by 4 table hepatocellular adenoma
justed test for odds ratio in the Add-2 adjusted asymptotic approach). Al-
though the dose-response pattern is not monotone, a significant trend exists
and therefore a biological gradient in Hills sense should be claimed. Again,
a poly-k adjusted analysis is highly recommended instead just crude propor-
tions.
4 Conclusion
With the proposed TmaxTukey-Williams crude and mortality-adjusted tumor rates
(using poly-k estimates) in long-term carcinogenicity bioassays can be eval-
uated appropriately. This test is sensitive against almost all dose-response
shapes, from linear to specific non-monotone.
This test can be formulated for the three effect sizes risk difference, risk ratio
(not explicitly shown) and odds ratio. The test is asymptotic valid for a
broad class of lm, glm, and glmm- models (latter not shown). To control the
coverage probability, approximations, such as Add-2 , are recommended for
the common small sample sizes, particularly when p0 = 0). Care is needed
when considering low correlated tests, such as multiple tumors because here
the conservatism may be unacceptable large.
Using the CRAN-packages tukeytrend, MCPAN, multcomp various modifi-
cations of TmaxTukey-Williams are possible, demonstrated for several real data ex-
amples (the R-code is in the appendix).
Further extensions to consider multiple experiments and historical controls,
as well as target concentrations vs. administered doses will be discussed next.
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5 Appendix: R-Code including datasets
library(xtable)
squam<-data.frame(
dose = c(0,0.0875, 0.175, 0.35, 0.70),
events = c(0, 2,2,6,6),
n = c(46, 45, 46, 47,44))
tf<-t(squam)
rownames(tf)<-c("Dose", "No. papilloma", "No. animals at risk")
xtable(tf, digits=0)
library(tukeytrend)
swaOR <-glm(cbind(events+1,(n-events)+1)~dose, data=squam, family= binomial(link="logit"))#
tuOR <- tukeytrendfit(swaOR, dose="dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
cOR <- summary(glht(model=tuOR$mmm, linfct=tuOR$mlf, alternative="greater"))
cOR$test$pvalues
library("ggplot2")
library(xtable)
COR<-fortify(cOR)[, c(1,5,6)]
colnames(COR)<-c("Test","Test stats", "p-value")
print(xtable(COR, digits=c(2,2,2,4), caption="Adjusted p-values",
label="tab:exa14"), include.rownames=FALSE)
############################# multiple tumors
library("reshape2")
data("miceF", package="SiTuR")
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miceF$Dose[miceF$group==0]<-0
miceF$Dose[miceF$group==1]<-37
miceF$Dose[miceF$group==2]<-75
miceF$Dose[miceF$group==3]<-150
miceL <-miceF[, c(2, 27:28, 30:32, 93), ]
miceM <- melt(miceL, c("ID", "Dose"), variable.name="Site", value.name="Success")
library("plyr")
miceN <- ddply(miceM, .(Dose, Site), summarize, Successes=sum(Success))
library("vcd")
mosaic(Success~Dose+Site, data=miceM, zero_size=0, color=TRUE)
library("multcomp")
glm24 <- glm(cbind(Successes + 1, 50 - (Successes+1)) ~ Dose,
subset(miceN, Site=="t24"), family=binomial())
glm25 <- glm(cbind(Successes + 1, 50 - (Successes+1)) ~ Dose,
subset(miceN, Site=="t25"), family=binomial())
glm27 <- glm(cbind(Successes + 1, 50 - (Successes+1)) ~ Dose,
subset(miceN, Site=="t27"), family=binomial())
glm28 <- glm(cbind(Successes + 1, 50 - (Successes+1)) ~ Dose,
subset(miceN, Site=="t28"), family=binomial())
glm29 <- glm(cbind(Successes + 1, 50 - (Successes+1)) ~ Dose,
subset(miceN, Site=="t29"), family=binomial())
tu24i <- tukeytrendfit(glm24, dose="Dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
tu25i <- tukeytrendfit(glm25, dose="Dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
tu27i <- tukeytrendfit(glm27, dose="Dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
tu28i <- tukeytrendfit(glm28, dose="Dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
tu29i <- tukeytrendfit(glm29, dose="Dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
tt5 <- combtt(tu24i, tu25i, tu27i, tu28i, tu29i)
TT5 <- summary(asglht(tt5, alternative="greater"))
library("ggplot2")
library(xtable)
T5<-fortify(TT5)[, c(1,5,6)]
colnames(T5)<-c("Test","Test stats", "p-value")
print(xtable(T5, digits=c(2,2,2,4), caption="Adjusted p-values",
label="tab:exa14"), include.rownames=FALSE)
tt24i <- tukeytrendfit(glm24, dose="Dose", scaling=c("ari", "ord", "arilog"))
tt25i <- tukeytrendfit(glm25, dose="Dose", scaling=c("ari", "ord", "arilog"))
tt27i <- tukeytrendfit(glm27, dose="Dose", scaling=c("ari", "ord", "arilog"))
tt28i <- tukeytrendfit(glm28, dose="Dose", scaling=c("ari", "ord", "arilog"))
tt29i <- tukeytrendfit(glm29, dose="Dose", scaling=c("ari", "ord", "arilog"))
tt30i <- tukeytrendfit(glm30, dose="Dose", scaling=c("ari", "ord", "arilog"))
tx<- combtt(tt24i, tt25i, tt27i, tt28i, tt29i)
stt10 <- summary(asglht(tx, alternative="greater"))
ta29i <- tukeytrendfit(glm29, dose="Dose", scaling="arilog") # alone
summary(glht(model=ta29i$mmm, linfct=ta29i$mlf, alternative="greater"))
############################ poly-k
library(MCPAN)
data("methyl", package="MCPAN")
data(methyl)
me <- methyl
# death: time of death, max(death)=length of study = 730 days
# poly-3 adjustment: (time of death/max(time))^k, k=3, for those animals without tumour at time of death!
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# Compute the poly-3 (-k)- weights at the level of single animals
me$weightpoly3 <- 1
me$weightpoly6 <- 1
# Animals without tumour at time of death get corrected sample size
wt0 <- which(me$tumour == 0)
me$weightpoly3[wt0] <- (me$death[wt0]/max(me$death))^3
me$weightpoly6[wt0] <- (me$death[wt0]/max(me$death))^6
#me
# check n.adj of the weights per group (should be the same with poly3ci in MCPAN; see below: OK)
# Put the Poly-3-weighted GLM into tukeytrendfit:
# See help(methyl) for the original dose levels:
me$dosegroup <- me$group
levels(me$dosegroup) <- c("0", "37", "75", "150")
me$dose <- as.numeric(as.character(me$dosegroup))
# Notice, the model use an identity link,
fitpoly3 <- glm(tumour ~ dose, data=me, family=binomial(link="identity"), weight=weightpoly3)
#summary(fitpoly3)
fitpoly3L <- glm(tumour ~ dose, data=me, family=binomial(link="logit"), weight=weightpoly3)
summary(fitpoly3L)
library(tukeytrend)
ttpoly3 <- tukeytrendfit(fitpoly3, dose="dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
compttpoly3 <- glht(model=ttpoly3$mmm, linfct=ttpoly3$mlf, alternative="greater")
ttpoly3L <- tukeytrendfit(fitpoly3L, dose="dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
compttpoly3L <- glht(model=ttpoly3L$mmm, linfct=ttpoly3L$mlf, alternative="greater")
library("ggplot2")
library(xtable)
polyL<-fortify(summary(compttpoly3L))
colnames(polyL)<-c("Comparisons","Test stats", "p-value")
print(xtable(polyL, caption="Adjusted by multiple covariates",
label="tab:exa14"), include.rownames=FALSE)
polyI<-fortify(summary(compttpoly3))
colnames(polyI)<-c("Comparisons","Test stats", "p-value")
print(xtable(polyI, caption="Adjusted by multiple covariates",
label="tab:exa14"), include.rownames=FALSE)
#########################poly 3 or 6 ###############################################
fitpoly6 <- glm(tumour ~ dose, data=me, family=binomial(link="identity"), weight=weightpoly6)
ttpoly6 <- tukeytrendfit(fitpoly6, dose="dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
compttpoly6 <- glht(model=ttpoly6$mmm, linfct=ttpoly6$mlf, alternative="greater")
tt36 <- combtt(ttpoly3,ttpoly6)
TT36 <- summary(asglht(tt36, alternative="greater"))
##########################################Hill criterion by Greim 2015
##########Study7 males hepatocell adenoma
library(xtable)
hep<-data.frame(
dose = c(0,121, 361, 1214),
events = c(0, 2,0,6),
n = c(52, 52, 52, 52))
th<-t(hep)
rownames(th)<-c("Dose", "No. hepatocellular adenoma", "No. animals at risk")
xtable(th, digits=0)
library(tukeytrend)
hepOR <-glm(cbind(events+1,(n-events)+1)~dose, data=hep, family= binomial(link="logit"))#
hOR <- tukeytrendfit(hepOR, dose="dose", scaling=c("ari", "ord", "arilog", "treat"), ctype="Williams")
HOR <- summary(glht(model=hOR$mmm, linfct=hOR$mlf, alternative="greater"))
HOR$test$pvalues
library("ggplot2")
library(xtable)
hor<-fortify(HOR)[, c(1,5,6)]
colnames(hor)<-c("Test","Test stats", "p-value")
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print(xtable(hor, digits=c(2,2,2,4), caption="Adjusted p-values",
label="tab:exa44"), include.rownames=FALSE)
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